DK1239857T3 - Dual-release-præparater af en cyclooxygenase-2-hæmmer - Google Patents

Dual-release-præparater af en cyclooxygenase-2-hæmmer

Info

Publication number
DK1239857T3
DK1239857T3 DK00989357T DK00989357T DK1239857T3 DK 1239857 T3 DK1239857 T3 DK 1239857T3 DK 00989357 T DK00989357 T DK 00989357T DK 00989357 T DK00989357 T DK 00989357T DK 1239857 T3 DK1239857 T3 DK 1239857T3
Authority
DK
Denmark
Prior art keywords
release
cyclooxygenase
inhibitor
dual
release preparations
Prior art date
Application number
DK00989357T
Other languages
English (en)
Inventor
Subhash Desai
Sreekant Nadkarni
Randy J Wald
Brincat Gary A De
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of DK1239857T3 publication Critical patent/DK1239857T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK00989357T 1999-12-22 2000-12-20 Dual-release-præparater af en cyclooxygenase-2-hæmmer DK1239857T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17173899P 1999-12-22 1999-12-22
US18160400P 2000-02-10 2000-02-10
US20227000P 2000-05-05 2000-05-05

Publications (1)

Publication Number Publication Date
DK1239857T3 true DK1239857T3 (da) 2006-07-31

Family

ID=27390015

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00989357T DK1239857T3 (da) 1999-12-22 2000-12-20 Dual-release-præparater af en cyclooxygenase-2-hæmmer

Country Status (26)

Country Link
US (1) US7220434B2 (da)
EP (1) EP1239857B1 (da)
JP (1) JP2003518062A (da)
KR (1) KR100717549B1 (da)
CN (1) CN1230167C (da)
AT (1) ATE323485T1 (da)
AU (1) AU780774C (da)
BR (1) BR0016705A (da)
CA (1) CA2394232C (da)
CY (1) CY1105050T1 (da)
CZ (1) CZ300745B6 (da)
DE (1) DE60027464T2 (da)
DK (1) DK1239857T3 (da)
ES (1) ES2258988T3 (da)
HK (1) HK1055677A1 (da)
IL (2) IL150353A0 (da)
MX (1) MXPA02006151A (da)
MY (1) MY127898A (da)
NO (1) NO20022987L (da)
NZ (1) NZ519467A (da)
PE (1) PE20010994A1 (da)
PL (1) PL201409B1 (da)
PT (1) PT1239857E (da)
SK (1) SK9032002A3 (da)
TW (1) TWI286073B (da)
WO (1) WO2001045706A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY120279A (en) 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US6924303B2 (en) 2000-06-13 2005-08-02 Wyeth Analgesic and anti-inflammatory compositions containing COX-2 inhibitors
JP2004503588A (ja) * 2000-07-13 2004-02-05 ファルマシア・コーポレーション 全身性疼痛および頭痛に対する選択的シクロオキシゲナーゼ−２阻害薬および血管調節化合物
ES2392705T3 (es) * 2000-10-02 2012-12-13 Usv Ltd. Composiciones farmacéuticas de liberación sostenida que contienen metformina y método para su producción
PT1443912E (pt) * 2001-10-12 2007-11-28 Elan Pharma Int Ltd Composições tendo uma combinação de características de libertação imediata e de libertação controlada
RU2004114552A (ru) * 2001-11-13 2005-02-20 Фармация Корпорейшн (Us) Пероральная дозированная форма сульфонамидного пролекарства
AU2002357366A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Multiple-pulse extended release formulations of clindamycin
WO2003057196A1 (en) * 2002-01-07 2003-07-17 Pharmacia Corporation Drug mixture with enhanced dissolution rate
WO2003074474A2 (en) 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
WO2004026235A2 (en) * 2002-09-20 2004-04-01 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
CN100360117C (zh) 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
US20060148877A1 (en) * 2002-11-26 2006-07-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
FR2861990B1 (fr) 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
EP1833476A1 (en) * 2004-11-23 2007-09-19 PLIVA HRVATSKA d.o.o. Extended release pharmaceutical composition of celecoxib
FR2881049B1 (fr) * 2005-01-24 2008-12-26 Vetoquinol Sa Sa Medicament destine a etre administre par voie orale comprenant un inhibiteur de la cyclo-oxygenase-2, et son procede de preparation
GB0501809D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Anti-migraine formulations
BRPI0620236A2 (pt) * 2005-12-23 2011-11-01 Lek Pharmaceuticals péletes dilacerantes
KR100762847B1 (ko) * 2006-01-27 2007-10-04 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
US10716798B2 (en) 2007-02-21 2020-07-21 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
US20090004231A1 (en) 2007-06-30 2009-01-01 Popp Shane M Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
WO2009063367A1 (en) * 2007-11-15 2009-05-22 Pfizer Products Inc. Dosage forms comprising celecoxib providing both rapid and sustained pain relief
US8323360B2 (en) * 2008-06-30 2012-12-04 3M Innovative Properties Company Method of crystallization
WO2010014952A2 (en) 2008-07-31 2010-02-04 Clarke Mosquito Control Products, Inc. Extended release tablet and method for making and using same
PL387415A1 (pl) * 2009-03-06 2010-09-13 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Kompozycja farmaceutyczna zawierająca celekoksyb oraz sposób jej wytwarzania
CA2758029A1 (en) * 2009-04-29 2011-11-04 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
US8563035B2 (en) * 2010-05-05 2013-10-22 Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi Oral tablet compositions of dexlansoprazole
EP2384746A3 (en) * 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
EP2590634B1 (en) * 2010-07-09 2016-03-09 BHV Pharma, Inc. Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
CN103462920A (zh) * 2012-06-06 2013-12-25 南京亿华药业有限公司 一种口服环加氧酶-2抑制剂塞来昔布的组合物
KR101446601B1 (ko) * 2014-01-29 2014-10-07 크리스탈지노믹스(주) 5-(4-(아미노설포닐)페닐)-2,2-디메틸-4-(3-플루오로페닐)-3(2h)-퓨라논을 포함하는 약학적 조성물 및 캡슐 제형
US10413520B2 (en) 2014-01-29 2019-09-17 Crystalgenomics, Inc. Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability
WO2018111991A1 (en) * 2016-12-14 2018-06-21 Druggability Technologies Ip Holdco Limited Pharmaceutical composition containing celecoxib
US11980691B2 (en) 2018-03-15 2024-05-14 R.P. Scherer Technologies, Llc Enteric softgel capsules

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0236571B2 (ja) * 1986-04-11 1990-08-17 Otsuka Pharma Co Ltd Jizokuseiseizai
IT1215726B (it) * 1988-01-18 1990-02-22 Alfa Wassermann Spa Formulazioni galeniche a cessione programmata.
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
CA2212836C (en) * 1995-02-13 2003-08-12 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
EP0892791B1 (en) * 1996-04-12 2003-03-05 G.D. Searle & Co. N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS
JPH1017497A (ja) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
DE69819351D1 (de) * 1997-09-11 2003-12-04 Nycomed Danmark As Roskilde Aus mehreren einzeleinheiten zusammengesetzte arzneimittel mit nicht-steroidalen wirkstoffen (nsaids)
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
WO2000053149A2 (en) * 1999-03-10 2000-09-14 G.D. Searle & Co. Method and composition for administering a cyclooxygenase-2 inhibitor
US20020107250A1 (en) * 2000-04-18 2002-08-08 Madhusudan Hariharan Rapid-onset formulation of a selective cyclooxygenase-2 inhibitor

Also Published As

Publication number Publication date
PE20010994A1 (es) 2001-09-21
CN1433309A (zh) 2003-07-30
NO20022987D0 (no) 2002-06-20
HK1055677A1 (en) 2004-01-21
CY1105050T1 (el) 2010-03-03
DE60027464D1 (de) 2006-05-24
TWI286073B (en) 2007-09-01
IL150353A0 (en) 2002-12-01
IL150353A (en) 2008-07-08
US20040242640A1 (en) 2004-12-02
CZ300745B6 (cs) 2009-07-29
CN1230167C (zh) 2005-12-07
CA2394232C (en) 2009-06-09
EP1239857B1 (en) 2006-04-19
PL355715A1 (en) 2004-05-17
SK9032002A3 (en) 2003-03-04
EP1239857A1 (en) 2002-09-18
AU780774C (en) 2006-09-21
MXPA02006151A (es) 2004-09-06
ES2258988T3 (es) 2006-09-16
CA2394232A1 (en) 2001-06-28
NZ519467A (en) 2004-02-27
AU2586801A (en) 2001-07-03
PL201409B1 (pl) 2009-04-30
KR100717549B1 (ko) 2007-05-11
NO20022987L (no) 2002-08-21
KR20020072554A (ko) 2002-09-16
ATE323485T1 (de) 2006-05-15
JP2003518062A (ja) 2003-06-03
DE60027464T2 (de) 2006-08-31
PT1239857E (pt) 2006-07-31
US7220434B2 (en) 2007-05-22
MY127898A (en) 2006-12-29
WO2001045706A1 (en) 2001-06-28
AU780774B2 (en) 2005-04-14
BR0016705A (pt) 2002-09-24

Similar Documents

Publication Publication Date Title
DK1239857T3 (da) Dual-release-præparater af en cyclooxygenase-2-hæmmer
HUP0100867A2 (hu) Celecoxib tartalmú gyógyászati készítmények
BR9908438A (pt) Tabletes de desintegração rápida
NO20013859D0 (no) Cyklooksygenase-2 inhibitorpreparater som raskt gir terapeutisk effekt
MXPA02006150A (es) Formulaciones de liberacion sostenida de un inhibidor de ciclooxigenasa-2.
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE530167T1 (de) Kombinierte dosierform mit einem cholesterinsenker, einem renin-angiotensin-hemmer und acetylsalicylsäure
DK1280799T3 (da) Orthosubstituerede anthranilsyreamider og anvendelse heraf som lægemidler
SE0101932D0 (sv) Pharmaceutical combinations
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
ATE460157T1 (de) Pharmazeutische metformintablette mit verlängerter freisetzung
MXPA06002722A (es) Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal.
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
TW200507829A (en) New combination
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
HRP20090022T3 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
DZ3459A1 (fr) Derives de 2h-1-benzopyran, procedes de preparation de ces derniers et compositions pharmaceutiques dans lesquels ils entrent.
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
NO20015488L (no) 14<beta>-H-steroler, farmasöytiske preparater som omfatter dem, og anvendelse av disse derivatene til fremstilling avmeioseregulerende medikamenter
DK1379253T3 (da) Fremgangsmåde til fremstilling og anvendelse af farmaceutiske formuleringer omfattende 7alfa, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-on og 17-estere heraf
MXPA04004290A (es) Composiciones de valdecoxib que se disgregan intraoralmente preparadas mediante un procedimiento de granulacion en lecho fluido.
DE60214412D1 (de) Simplifizierte sarcodictyn-derivate als anti-tumor-mittel
NO20013901L (no) Umettede kolestanderivater og deres anvendelse for fremstilling av meioseregulerende medikamenter
AR031087A1 (es) Composiciones de liberacion doble de un inhibidor de la ciclooxigenasa-2
MA26484A1 (fr) Nouveau medicament pour traitement des hemorroides par voie orale.